"Antineoplastic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
| Descriptor ID |
D000970
|
| MeSH Number(s) |
D27.505.954.248
|
| Concept/Terms |
Antineoplastic Agents- Antineoplastic Agents
- Agents, Antineoplastic
- Antineoplastic Drugs
- Drugs, Antineoplastic
- Antineoplastics
- Chemotherapeutic Anticancer Drug
- Drug, Chemotherapeutic Anticancer
- Antitumor Drugs
- Drugs, Antitumor
- Cancer Chemotherapy Agents
- Agents, Cancer Chemotherapy
- Chemotherapy Agents, Cancer
- Cancer Chemotherapy Drugs
- Chemotherapy Drugs, Cancer
- Drugs, Cancer Chemotherapy
- Chemotherapeutic Anticancer Agents
- Agents, Chemotherapeutic Anticancer
- Anticancer Agents
- Agents, Anticancer
- Antitumor Agents
- Agents, Antitumor
|
Below are MeSH descriptors whose meaning is more general than "Antineoplastic Agents".
Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Agents".
This graph shows the total number of publications written about "Antineoplastic Agents" by people in this website by year, and whether "Antineoplastic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 1996 | 1 | 0 | 1 |
| 1997 | 3 | 1 | 4 |
| 1999 | 4 | 1 | 5 |
| 2000 | 1 | 1 | 2 |
| 2001 | 2 | 0 | 2 |
| 2002 | 6 | 3 | 9 |
| 2003 | 2 | 2 | 4 |
| 2004 | 4 | 2 | 6 |
| 2005 | 7 | 1 | 8 |
| 2006 | 10 | 4 | 14 |
| 2007 | 6 | 3 | 9 |
| 2008 | 9 | 3 | 12 |
| 2009 | 16 | 5 | 21 |
| 2010 | 16 | 8 | 24 |
| 2011 | 18 | 9 | 27 |
| 2012 | 15 | 7 | 22 |
| 2013 | 24 | 10 | 34 |
| 2014 | 20 | 6 | 26 |
| 2015 | 31 | 8 | 39 |
| 2016 | 36 | 8 | 44 |
| 2017 | 21 | 8 | 29 |
| 2018 | 25 | 6 | 31 |
| 2019 | 19 | 8 | 27 |
| 2020 | 20 | 5 | 25 |
| 2021 | 17 | 5 | 22 |
| 2022 | 12 | 0 | 12 |
| 2023 | 7 | 0 | 7 |
| 2024 | 6 | 11 | 17 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antineoplastic Agents" by people in Profiles.
-
Targeting Oncogenic RET Kinase by Simultaneously Inhibiting Kinase Activity and Degrading the Protein. J Med Chem. 2025 Jan 09; 68(1):81-94.
-
Histone acetyltransferases as promising therapeutic targets in glioblastoma resistance. Cancer Lett. 2024 Nov 01; 604:217269.
-
Development of Novel Indole-Based Covalent Inhibitors of TEAD as Potential Antiliver Cancer Agents. J Med Chem. 2024 Sep 26; 67(18):16270-16295.
-
A Database Tool Integrating Genomic and Pharmacologic Data from Adrenocortical Carcinoma Cell Lines, PDX, and Patient Samples. Cancer Res Commun. 2024 09 01; 4(9):2384-2398.
-
Tailored chemotherapy: Innovative deep-learning model customizing chemotherapy for high-grade serous ovarian carcinoma. Clin Transl Med. 2024 Sep; 14(9):e1774.
-
PF-06952229, a selective TGF-?-R1 inhibitor: preclinical development and a first-in-human, phase I, dose-escalation study in advanced solid tumors. ESMO Open. 2024 Sep; 9(9):103653.
-
Acetalax (Oxyphenisatin Acetate, NSC 59687) and Bisacodyl Cause Oncosis in Triple-Negative Breast Cancer Cell Lines by Poisoning the Ion Exchange Membrane Protein TRPM4. Cancer Res Commun. 2024 08 01; 4(8):2101-2111.
-
Chemoreactive 2,5-Diketopiperazines from a Penicillium sp., Structure Revision of Reported Analogues and Proposed Facile Transformation Pathways. J Nat Prod. 2024 Jul 26; 87(7):1826-1837.
-
Oncology drug pricing: potential Medicare savings on cancer-directed and supportive care medications through the Mark Cuban cost plus drug model. Oncologist. 2024 Jul 05; 29(7):e918-e921.
-
The Novel ATR Inhibitor M1774 Induces Replication Protein Overexpression and Broad Synergy with DNA-targeted Anticancer Drugs. Mol Cancer Ther. 2024 Jul 02; 23(7):911-923.